EP1007035A1 - Agents antineoplastiques a base de polythiofene - Google Patents

Agents antineoplastiques a base de polythiofene

Info

Publication number
EP1007035A1
EP1007035A1 EP96945379A EP96945379A EP1007035A1 EP 1007035 A1 EP1007035 A1 EP 1007035A1 EP 96945379 A EP96945379 A EP 96945379A EP 96945379 A EP96945379 A EP 96945379A EP 1007035 A1 EP1007035 A1 EP 1007035A1
Authority
EP
European Patent Office
Prior art keywords
thienyl
alkyl
substituted
mono
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96945379A
Other languages
German (de)
English (en)
Other versions
EP1007035A4 (fr
Inventor
Ching-Te Chang
Ching-Jer Chang
Chen-Tao Lee
Fen-Lan Lin
Jih-Dar Tsai
Curtis L. Ashendel
Thomas C. K. Chan
Robert L. Geahlen
David J. Waters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute ITRI
Purdue Research Foundation
Original Assignee
Industrial Technology Research Institute ITRI
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI, Purdue Research Foundation filed Critical Industrial Technology Research Institute ITRI
Publication of EP1007035A1 publication Critical patent/EP1007035A1/fr
Publication of EP1007035A4 publication Critical patent/EP1007035A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Definitions

  • the present invention relates to compositions and a method for treating a patient having a tumor. More specifically, the present invention relates to the treatment of such patients with an effective amount of a polythiophene derivative.
  • the control and cure of cancer represents one of our most challenging health problems.
  • the treatment of cancer can be approached by several modes of therapy including surgery, radiation, chemotherapy or a combination of any of these treatments.
  • Chemotherapy continues to be an indispensable therapy for inoperable or metastatic forms of the disease.
  • the selection of natural compounds, or the synthesis of new compounds having effective anticancer activity is complicated by the still limited knowledge of cancer cell biology and biochemistry. Therefore, development of new effective anti-tumor agents will remain heavily dependent on screening compounds to discover novel compounds having cytotoxic activity.
  • such compounds exhibit enhanced cytotoxicity against tumor cells relative to their cytotoxicity to normal cells.
  • Natural products have a history of providing novel, clinically useful anticancer drugs. Many active natural products have also served as prototypes for the development of new analogs of clinical and preclinical importance. Some specific examples are the Vinca alkaloids (vincristine, vinblastine, vindesine and vinorelbine) , podophyllotoxins etoposide and teniposide) , taxanes (taxol, taxotere) , camptothecins (10-hydroxycamptothecin, 9- dimethylaminomethylcamptothecin, 9-aminocamptothecin and CPT-11) , ho oharringtonine, adriamycin, daunomycin, bleomycin, mitomycin, idamycin, plicamycin and dactino ycin.
  • Vinca alkaloids vincristine, vinblastine, vindesine and vinorelbine
  • podophyllotoxins etoposide and teniposide taxanes
  • NCI National Cancer Institute
  • This in vitro prescreening system is based on the measurement of antitumor cytotoxicity against human tumor cell line panels consisting of approximately 60 cell lines of major human tumors (including leukemia and slower growing tumor cells such as lung, colon, breast, skin, kidney, etc.).
  • the most important advantage of the new in vitro screening panels is the opportunity to identify compounds that are selectively more cytotoxic to cells of slowly growing solid tumors than to rapidly growing leukemia cells.
  • Thiophenes are sulfur containing heterocyclic compounds that are distributed widely among the species of the Asteraceae (Compositaie) family, including many species with known medicinal uses.
  • the natural thiophene compounds are thought to play an important role in the chemical defense of plants against herbivorous insects and other pests.
  • Natural thiophenes have been previously described as having cytotoxic activities upon exposure to long wavelength ultraviolet light. Photochemical studies suggest that thiophene phototoxicity is based primarily on the production of toxic singlet oxygen by a type II photodynamic process. However, polythiophene compounds also exhibit cytotoxic activity in the absence of light activation. More particularly, we have demonstrated that the polythiophene derivatives of the present invention are effective antitumor agents.
  • n 0, 1 or 2
  • R ⁇ is H, CHO, CH 2 0H or CH 2 NH 2
  • R 2 and R 3 are independently optionally substituted 2- or 3- thienyl.
  • the present invention is directed to polythiophene compounds, their pharmaceutical compositions and methods utilizing such compounds/compositions for treating patients having tumors.
  • the polythiophene compounds are effective antitumor agents against slow growing tumors. Generally they have been found to exhibit high selective cytotoxicity for individual tumor cell lines.
  • the compounds of the present invention are polythiophene compounds of the formula:
  • n 0, 1 or 2 ,
  • R j _ is H, CH 2 0H, CHO, CH 2 NH 2 ,
  • R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , C 1 -C 4 alkyl, C0C 1 -C 17 alkyl, or tetrahydropyranyl ;
  • R 5 is H or ⁇ C alkyl
  • R 6 and R 7 are independently H, C ⁇ ⁇ -C ⁇ j alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
  • R 8 is C- L -Cy alkyl, or C ⁇ C ? alkenyl
  • R 9 and R 10 are independently H, C- ⁇ C j alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, COC 6 H 4 OH(p);
  • R l ⁇ is NHR 4 or 0R 5 ;
  • R 12 is COOR 5 , CH(OR 4 )CH 2 OR 13 or CH(OCOC 1 -C 4 alkyl) CH 2 OR 5 ;
  • R 13 is H, COCH 2 CH 2 COOH, or C0C 1 -C 17 alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when R-L is H, R 2 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, 3- formy1-2-thienyl and mono- or di- substituted 3-thienyl, and R 3 is selected from the group consisting of 3-thienyl, di- substituted 2-thienyl, hydroxymethyl- or aminomethyl- substituted 2-thienyl, mono- or di- substituted 3-thienyl and formyl substituted 2-thienyl.
  • CH 2 NH 2 , CH 2 0H or CHO exhibit cytotoxic selectivity against transformed human cells.
  • Still another preferred group of polythiophene compounds of this invention are those of the above formula wherein R 2 is optionally substituted 2-thienyl and R 3 is 3- or 4-substituted-2-thienyl wherein the substitutes are selected from CH 2 OH, CHO and CH 2 NH 2 .
  • n 0, 1 or 2
  • R ⁇ is H, CH 2 OH, CHO, CH 2 NH 2 ,
  • R 2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl
  • R 3 is selected from the group consisting of 3-thienyl, mono- or di- substituted 3- thienyl and di- substituted 2-thienyl
  • R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , C 1 -C 4 alkyl, or 00 ⁇ - C 17 alkyl ;
  • R 5 is H or C ⁇ C- ? alkyl;
  • R 6 and R 7 are independently H, C- ⁇ alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
  • R 8 is C-L-C-7 alkyl, or C_-C- j alkenyl
  • R 9 and R 10 are independently H, C_-C ⁇ alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, COC 6 H 4 OH(p); R l ⁇ is NHR 4 or OR 5 ;
  • R 12 is C00R 5 , CH(OR 4 )CH 2 OR 13 or CH (OCOC-L- ⁇ alkyl) CH 2 OR 5 ;
  • R 13 is H, COCH 2 CH 2 COOH, or COC-L-C- ⁇ alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby.
  • the polythiophene compounds of this invention are readily formulated into pharmaceutical compositions, also within the scope of this invention, for use in the presently described method for treatment of patients having tumors.
  • the pharmaceutical composition comprises an anti-tumor effec- tive amount of a polythiophene compound of the formula:
  • n 0, 1 or 2 ,
  • R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , or COC 1 -C 17 alkyl;
  • R 5 is H or C ⁇ -C ⁇ alkyl;
  • R 6 and R 7 are independently H, C 1 -C 4 alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
  • R 8 is C 1 -C 7 alkyl, or ⁇ -C y alkenyl
  • R 9 and R 10 are independently H, C 1 -C 7 alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, or COC 6 H 4 OH(p) ;
  • R ⁇ is NHR 4 or OR 5 ;
  • R 12 is C00R 5 , CH(OR 4 )CH 2 OR 13 or CH(0C0C 1 -C 4 alkyl) CH 2 OR 5 ;
  • R 13 is H, COCH 2 CH 2 COOH, or C0C 1 -C 17 alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby; with the proviso, that when R x is H, R 2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3- thienyl, and R 3 is selected from the group consisting of 3- thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl, and a pharmaceutically acceptable carrier.
  • n 0, l or 2 ,
  • R ⁇ is H, CH 2 0H, CHO, CH 2 NH 2 ,
  • R 2 is selected from the group consisting of 2-thienyl, 3-thienyl, mono- or di- substituted 2-thienyl, or mono- or di- substituted 3-thienyl
  • R 4 is H, CO(CH 2 ) 2 C0 2 H, (CH 2 ) 2 OCH 3 , C 1 -C 4 alkyl or 00 ⁇ - C_ ⁇ alkyl;
  • R 5 is H or C ⁇ C ⁇ alkyl
  • R 6 and R 7 are independently H, C- ⁇ -C ⁇ alkyl, or mono- or di- hydroxyC 2 -C 4 alkyl;
  • R 8 is C;L-C 7 alkyl, or C -C ⁇ alkenyl
  • R 9 and R 10 are independently H, C_-C ⁇ alkyl, COOR 5 , CN, CH(OR 4 )COOR 5 , Br, CO-thienyl, or COC 6 H 4 OH(p) ;
  • R l ⁇ is NHR 4 or OR 5 ;
  • R 12 is COOR 5 , CH(OR 4 )CH 2 OR 13 or alkyl) CH 2 OR 5 ;
  • R 13 is H, COCH 2 CH 2 COOH, or COC ⁇ C- ⁇ alkyl; cyclodextrin complexes of such compound and when R 2 or R 3 is thienyl substituted with CH 2 NR 6 R 7 , the pharmaceutically acceptable salt of the compound represented thereby, and a pharmaceutically acceptable carrier.
  • the present compounds are readily prepared using art- recognized chemical-synthesis procedures as exemplified hereinbelow. The art is replete with descriptions of the chemistry and synthesis of thiophene and polythiophene compounds. Tables 1, 2, 3 and 4 hereinbelow show several polythiophene compounds that have been tested at the National Cancer Institute. The growth inhibition profiles of several polythiophenes are shown in Tables 5, 6 and 7. The unusually strong activities against solid tumors are predictive of significant therapeutic potency for the treatment of cancer.
  • THP tetrahydropyranyl Ac: actyl TS: tosyl Et: ethyl TH: thienyl
  • Table 5 The growth inhibition of the human cancer cell lines by polythiophene Log 10 GI 50 (M)
  • Table 6 The growth inhibition of the human cancer cell lines by chemically modified a-polythiophene derivatives
  • the cytotoxic activity of the present polythiophene compounds have been measured utilizing three different assays or screens.
  • the first screen measures the cytotoxicity against a panel of sixty different human tumor cell lines.
  • This assay provides data regarding the general cytotoxicity of an individual compound.
  • this type of assay is useful in identifying compounds which have enhanced cytotoxic activity against slow growing tumors as compared to faster growing tumor cells such as leukemia tumor cell lines.
  • the identification of such compounds is critical since previously identified antitumor agents have low cytotoxic activity against slower growing tumors.
  • the specificity of a compound for a limited number of tumor cell lines also indicates that such a compound will likely be less cytotoxic to normal cells.
  • the specificity of a cytotoxic compound for tumor cell lines relative to normal cells is an important characteristic of an effective antitumor agent. Antitumor cytotoxicity data for the National Cancer
  • Relative cytotoxicity is displayed by projecting bars to the right or left of the mean, depending on whether cell sensitivity to a test compound is more or less than average. The length of a bar is indicative of differential cytotoxicity against a specific type of tumor cells or tumor panels.
  • the cytotoxic selectivity is assessed by comparing compound cytotoxicity against transformed cells and normal cells. IC 50 values were compared between treated TBE cells (ras-transformed human bronchial epithelial cells) and NHBE cells (Normal human bronchial epithelial cells) .
  • NMBE normal human bronchial epithelial cells
  • TBE ras-transformed human bronchial epithelial cells
  • the antitumor cytotoxicity of the thiophene compounds tested in the first two in vitro assays was measured by a microculture assay using either 3- (4 , 5-dimethylthiazol-2-yl) -2 , 5-diphenyltetrazolium bromide (MTT) or sulforhodamine B (SRB) .
  • MTT 5-dimethylthiazol-2-yl
  • SRB sulforhodamine B
  • Table 8 Selective cytotoxicity against ras-oncogene transformed human bronchial epithelial cells
  • This assay has an advantage over in vivo assay in that results are obtained within a week as opposed to several months.
  • the assay was carried out in 96-well microtiter plates.
  • the MTT assay is based on the production of a dark blue formazan product by dehydrogenase in the mitochondria of live tumor cells after exposure to drug for 6 days [M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker and M.R.
  • GI 50 Antitumor cytotoxicity is reported as GI 50 , effect drug dose at which cell growth is retarded to 50% of control culture of tumor cells.
  • the active compounds are defined as those compounds having GI 50 values that are less than 10 -4 M or 10 ⁇ g/ml.
  • the in vivo data was derived from experiments in which human tumors are transplanted into immune deficient mice and allowed to grow for two days prior to treatment with a polythiophene composition of this invention. See Example 48 and accompanying Tables 9 and 10. Data obtained from studies using heterotransplanted tumors in immune deficient mice are recognized as well-correlated with the effectiveness of these agents in clinical studies (Giovanella, B.C. et al. Cancer 52(7): 1146 (1983).
  • the present invention further provides pharmaceutical formulations comprising an effective amount of a polythiophene compound for treating a patient having a tumor.
  • an effective amount of the polythiophene compound is defined as the amount of the compound which, upon administration to a patient, inhibits growth of tumor cells, kills malignant cells, reduces the volume or size of the tumors or eliminates the tumor entirely in the treated patient.
  • the effective amount to be administered to a patient is typically based on body surface area, patient weight, and patient condition. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich, E.J., et al., Cancer Chemother. Rep. , 50 (4): 219 (1966).
  • Body surface area may be approximately determined from patient height and weight (see e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, pages 537-538 (1970)).
  • An effective amount of the polythiophene compounds in the present invention can range from about 5 mg/kg. to about
  • 500 mg/kg more preferably from about 5 mg/kg to about 250 mg/kg, and most preferably about 5 to about 150 mg/kg.
  • Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage and the possibility of co-usage with other therapeutic treatments including other anti-tumor agents, and radiation therapy.
  • the pharmaceutical formulation may be administered via the parenteral route, including subcutaneously, intraperitoneally, intramuscularly and intravenously.
  • parenteral dosage forms include aqueous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable liquid carrier.
  • the polythiophene compound is dissolved in a saline solution containing 5% of dimethyl sulfoxide and 10% Cremphor EL (Sigma Chemical Company) .
  • solubilizing agents such as cyclodextrins, which form specific, more soluble complexes with the present polythiophene compounds, or other solubilizing agents well- known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the polythiophene compounds.
  • the present compound can also be formulated into dosage forms for other routes of administration utilizing well- known methods.
  • the pharmaceutical compositions can be formulated, for example, in dosage forms for oral administration in a capsule, a gel seal or a tablet.
  • Capsules may comprise any well-known pharmaceutically acceptable material such as gelatin or cellulose derivatives.
  • Tablets may be formulated in accordance with conventional procedure by compressing mixtures of the active polythiopene and solid carriers, and lubricants well-known to those familiar with the art. Examples of solid carriers include starch, sugar, bentonite.
  • the compounds of the present invention can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and a conventional fillers and tableting agents.
  • the following examples are provided to illustrate various embodiments of Applicants' invention, and are not intended to in any way limit the scope of the invention as set forth in this specification and appended claims.
  • the extract was dried, concentrated and separated by silica gel chromatography eluted first with ethyl acetate/n-hexane (1:9) to recover starting material, and then with ethyl acetate/n-hexane (3:7) to obtained 5-formyl- ⁇ -terthiophene.
  • P0C1 3 (2 ml) was added into dimethyl formamide (30 ml) slowly under nitrogen gas atmosphere in ice bath and stirred for 1 hour.
  • Ethyl propiolate (78 mg) was dissolved in benzene (3 ml) . 5-Iodo- ⁇ -terthiophene (0.2 g) was added immediately and stirred. A mixture of Cul (0.05 g) , benzyltriethylammonium chloride (0.05 g) , catalyst Pd(PPh 3 ) 4 (0.1 g) and 5 ml of NaOH solution (2.5 N) were mixed together. The temperature of the mixture was then raised to 40°C and stirred for 5 more hours. Then 5 ml of NH 4 C1 solution was added. The reaction solution was extracted with ethyl acetate.
  • the extract was washed with 10 ml of HCl (10%) for 3 times, 50 ml of water twice and dried over anhydrous magnesium sulfate.
  • the residual solid after evaporation was purified by silica gel column chromatography, eluted with ethyl acetate/n-hexane (1/3). Light yellowish product (0.21 g, 75%) was obtained and the melting point thereof was 67°C.
  • Acetylene gas was bubbled into tetrahydrofuran (30 ml) for 30 minutes.
  • Ethyl magnesium bromide 25 ml was added.
  • the eluant was ethyl acetate/n-hexane (7/3) .
  • the white platelet crystal thus obtained was further recrystallized with ethyl acetate/n-hexane mixture.
  • the melting point of the product was 60°C.
  • Phosphorus oxychloride (“P0C1 3 ”) (1 ml) was added into dimethyl formamide (20 ml) slowly under nitrogen gas atmosphere in ice bath and stirred for 1 hour.
  • the dimethyl formamide solution (5 ml) of 5-hydroxymethyl- 2 , 2 '-bithiophene (0.5 g) was dropped in slowly.
  • the mixture was stirred for half an hour at room temperature, then the temperature was raised to 50°C and was further stirred for 3 hours.
  • the reaction solution was poured into potassium carbonate ice water solution. Then the solution was extracted with 100 ml of ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate.
  • NSC code # 647453 5-Hydroxymethyl-5'-formyl-2, 2 '-bithiophene (0.2 g) and pyridine (1 ml) were mixed together. Acetic anhydride (1 ml) was added slowly into the mixture with stirring. Ethyl acetate (200 ml) and water (50 ml) were added 2 hours later. The ethyl acetate layer was washed with weak base, weak acid and water. The product was concentrated and purified by column chromatography, eluted with ethyl acetate/n-hexane (1/9) . Light yellowish crystals were obtained. The melting point of the crystal was 89-91°C.
  • the yield was 95%.
  • the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) . After removal of solvent, the residue was dissolved in 50 ml of tetrahydrofuran under nitrogen stream and dropped in 1 ml of Ethyl Grignard reagent and stirred at room temperature for 3 hours. The solution was monitored by thin layer chromatography. After the reaction was completed, then the solution was extracted with 300 ml of ethyl acetate and 50 ml of water. After removal of solvent, the residual solid was purified by column chromatography, eluted with ethyl acetate/n-hexane (3/7) .
  • polythiophene compounds prepared in accordance with this invention are those represented by the following structural formulas.
  • NSC 666165-Z/0-1/30
  • Tumor cells were obtained from normal human bronchial epithelial cells transfected ' with plasmic HI carrying v-Harvey-ras (H-ras) oncogene via protoplast fusion (G.H. Yoakum, J.F. Lechner, E.W. Gabrielson, B.E. Korba, L. Malan-Shibley, J.C. Willey, M.G. Valerio, A.M. Shamsuddin, B.F. Trump and C.C. Harris, Science 227, 1174, 1985.
  • the TBE cells were implanted subcutaneously on day 0 of the experiment. Each test group consists of five mice. The compounds tested were dissolved in a saline solution or a saline solution containing 5% of dimethylsulfoxide and 10% cremphor EL (Sigma Chemical Company, St. Louis, MO) , and were administered intraperitoneously starting on day 2. The solution was administered every four days for a total of four treatments. Tumor volumes were measured every week. The antitumor activity was measured as % of growth inhibition, which is defined by the percentage of the median tumor volume reduction per week of the treated mice divided by the median tumor volume per week of the controlled mice (Tables 9 and 10) .
  • Tumor cells ras-transformed human bronchial epithelial cells (2.5 x 10 6 cells/mouse)
  • Tumor cells ras-transformed human bronchial epithelial cells (4.0 x 10 6 cells/mouse)
  • Tumor growth inhibition was determined by comparing the volume/weight of the tumors of the treated mice in the test group with that of the tumors in the control group mice. The data are presented as the percent of treated tumor volume/weight to control tumor volume/weight (T/C %) with the day the measurement was taken indicated in parenthesis.
  • a. 660641 hydroxypropyl-B-cyclodextrin inclusion complex of 2-aminohydroxy- ⁇ - terthiophene tartarated (2:1 molar ratio; FW:3428) (Estimated 50% lethal dosage: 1550 mg/kg.)
  • 647455 2-formyl-5"-hydroxymethyl- ⁇ -terthiophene
  • 637388 2-hydroxymethyl - ⁇ -terthiophene
  • 658878 2,4"- ⁇ lihydroxymethyl- ⁇ -terthiophene
  • T/C tumor volume or weight of treated mice/tumor volume or weight of control (untreated) mice. The number shown in the parenthesis is the day when the tumor volume or weight is measured.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a trait à des composés à base de polythiofène, efficaces en tant qu'agents antinéoplastiques. Les composés préférés de l'invention répondent à la formule (I) dans laquelle la valeur de n est comprise entre 0 et 2 et dans laquelle R2 et R3 représentent 2-thiényle ou 3-thiényle éventuellement substitués. Il s'est avéré que ces composés font montre d'une action cytotoxique sélective à l'encontre de cellules humaines transformées. On attend de compositions à usage pharmaceutique contenant les composés à base de polythiofène susmentionnés qu'elles aient une action chimiothérapeutique efficace contre des tumeurs à croissance lente et ce, si l'on se réfère aux criblages effectués sur des lignées cellulaires tumorales. L'invention porte également sur une méthode thérapeutique à l'intention de patients soufrant de tumeurs, méthode faisant intervenir les composés susmentionnés à base de polythiofène.
EP96945379A 1996-11-26 1996-11-26 Agents antineoplastiques a base de polythiofene Withdrawn EP1007035A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/019118 WO1998023269A1 (fr) 1996-11-26 1996-11-26 Agents antineoplastiques a base de polythiofene

Publications (2)

Publication Number Publication Date
EP1007035A1 true EP1007035A1 (fr) 2000-06-14
EP1007035A4 EP1007035A4 (fr) 2000-11-22

Family

ID=22256220

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96945379A Withdrawn EP1007035A4 (fr) 1996-11-26 1996-11-26 Agents antineoplastiques a base de polythiofene

Country Status (5)

Country Link
EP (1) EP1007035A4 (fr)
JP (1) JP2001506624A (fr)
AU (1) AU1564797A (fr)
CA (1) CA2272275A1 (fr)
WO (1) WO1998023269A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513544A (ja) * 2004-09-14 2008-05-01 ノースウェスタン ユニバーシティ カルボニル官能化チオフェン化合物および関連する装置構造
JP5646495B2 (ja) * 2008-10-17 2014-12-24 バイオクロミクス・ニューコ・アクチボラグ 療法において使用するための新規チオフェン化合物
CN113603674B (zh) * 2021-07-23 2022-10-14 上海应用技术大学 一种5,5’位取代的3,3’-联噻吩衍生物、合成方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937256A (en) * 1988-06-01 1990-06-26 Basf Aktiengesellschaft Thiophene compounds
US5508440A (en) * 1993-06-04 1996-04-16 Industrial Technology Research Institute Hydroxymethylpolythiophene derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050442A (en) * 1957-05-31 1962-08-21 Philips Corp Method of destroying nematodes with polythienyl compounds
US5045563A (en) * 1986-08-26 1991-09-03 Her Majesty The Queen In Right Of Canada, As Represented By Minister Of National Defence Of Her Majesty's Canadian Government Phototoxic compounds for use as insect control agents
US4861692A (en) * 1986-12-22 1989-08-29 Fuji Electric Company, Ltd. Electrophotographic photosensitive material containing thiophene compound
ES2073661T3 (es) * 1990-04-27 1995-08-16 Duphar Int Res Metodo para la isomerizacion fotoquimica de compuestos organicos bajo la influencia de un fotosensibilizador.
US5578636A (en) * 1994-04-08 1996-11-26 Purdue Research Foundation Polythiophene anti-tumor agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937256A (en) * 1988-06-01 1990-06-26 Basf Aktiengesellschaft Thiophene compounds
US5508440A (en) * 1993-06-04 1996-04-16 Industrial Technology Research Institute Hydroxymethylpolythiophene derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASHENDEL C L_(A): "Structure-activity relationship of alpha-terthiophene series for inhibition of protein kinase C and cytotoxicity." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 2604, March 1995 (1995-03), XP002147664 *
ASHENDEL C L_(A): "Terthiophenes as novel inhibitors of protein kinase C." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 2661, March 1994 (1994-03), XP002147662 *
See also references of WO9823269A1 *
WATERS D J_(A) T_(A): "In vivo antitumor efficacy of a novel polythiophene against ras-transformed human bronchial epithelial cells." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 2705, March 1996 (1996-03), XP002147663 *

Also Published As

Publication number Publication date
AU1564797A (en) 1998-06-22
EP1007035A4 (fr) 2000-11-22
CA2272275A1 (fr) 1998-06-04
WO1998023269A1 (fr) 1998-06-04
JP2001506624A (ja) 2001-05-22

Similar Documents

Publication Publication Date Title
AU2013265119B2 (en) Catechol O-methyltransferase activity inhibiting compounds
JPH01211576A (ja) Ｐａｆ拮抗体としての新規２，５‐ジアリールテトラヒドロフラン及びその類縁体
US20040063662A1 (en) Selenophene anti-tumor agents
US5578636A (en) Polythiophene anti-tumor agents
EP1646616A2 (fr) Derives de la combretastatine a action cytotoxique
WO1998023269A1 (fr) Agents antineoplastiques a base de polythiofene
CN113620969B (zh) 带桥环的环己烷二羧酸衍生物及其药物组合物和应用
AU2007249952B2 (en) Modified chalcone compounds as antimitotic agents
CN104650109B (zh) 紫杉烷类化合物
AU727123B2 (en) Selenophene anti-tumor agents
US5994394A (en) Polyheterocyclic compounds
CN114230466A (zh) 二氯乙酸偶联二苯乙烷类化合物、其制备方法和应用
US4520028A (en) α-Aminobutyric acid transaminase inhibitors
TW304951B (en) Polythiophene anti-tumor compound and pharmaceutical composition
US4524076A (en) Novel γ-aminobutyric acid transaminase inhibitors
AU2002238760B2 (en) Antiproliferative agents
NL8501776A (nl) Geneesmiddelprecursors, werkwijze voor het bereiden daarvan, en farmaceutische preparaten op basis daarvan.
Schachtner et al. Synthesis and anticonvulsive activity of thiolosigamone
KR100501843B1 (ko) 새로운 항암성 비타민 ｄ₃유도체
KR100248329B1 (ko) 신규한 제니핀 유도체 및 이를 유효성분으로 하는 간질환치료제조성물
JPH1180152A (ja) 多複素環式化合物
Stecoza et al. SYNTHESIS AND STRUCTURE ELUCIDATION OF SOME NEW O-ACYL-OXIMINO-DIBENZO [b, e] THIEPINES AND O-ACYL-OXIMINO-DIBENZO [b, e] THIEPINE-5, 5-DIOXIDES
AU2002238760A1 (en) Antiproliferative agents
NO175099B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 1,3,5-tritianderivater
JPH07196646A (ja) ヒドロキシメチルポリチオフェン誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 20001006

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001215